- Home
- GNLX vs ACHV Comparison
GNLX vs ACHV Comparison
Compare GNLX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ACHV
- Stock Information
- Founded
- GNLX 2001
- ACHV N/A
- Country
- GNLX United States
- ACHV United States
- Employees
- GNLX N/A
- ACHV N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GNLX Health Care
- ACHV Health Care
- Exchange
- GNLX Nasdaq
- ACHV Nasdaq
- Market Cap
- GNLX 128.0M
- ACHV 131.3M
- IPO Year
- GNLX 2023
- ACHV N/A
- Fundamental
- Price
- GNLX $3.91
- ACHV $2.96
- Analyst Decision
- GNLX Strong Buy
- ACHV Strong Buy
- Analyst Count
- GNLX 4
- ACHV 2
- Target Price
- GNLX $17.75
- ACHV $16.00
- AVG Volume (30 Days)
- GNLX 151.7K
- ACHV 1.6M
- Earning Date
- GNLX 11-13-2025
- ACHV 11-06-2025
- Dividend Yield
- GNLX N/A
- ACHV N/A
- EPS Growth
- GNLX N/A
- ACHV N/A
- EPS
- GNLX N/A
- ACHV N/A
- Revenue
- GNLX N/A
- ACHV N/A
- Revenue This Year
- GNLX N/A
- ACHV N/A
- Revenue Next Year
- GNLX N/A
- ACHV N/A
- P/E Ratio
- GNLX N/A
- ACHV N/A
- Revenue Growth
- GNLX N/A
- ACHV N/A
- 52 Week Low
- GNLX $1.95
- ACHV $1.84
- 52 Week High
- GNLX $5.89
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- GNLX 59.55
- ACHV 51.21
- Support Level
- GNLX $3.76
- ACHV $2.97
- Resistance Level
- GNLX $3.61
- ACHV $3.30
- Average True Range (ATR)
- GNLX 0.25
- ACHV 0.21
- MACD
- GNLX 0.05
- ACHV -0.01
- Stochastic Oscillator
- GNLX 67.03
- ACHV 45.16
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.